Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
MIBG plus dinutuximab met of zonder vorinostat bij gerecidiveerd/refractair neuroblastoom
sep 2025 | Neuro-oncologie